Custom Software

AI Healthcare Regulations 2026: Complete Compliance Guide

AI in healthcare is moving faster than the regulations governing it — but regulators are catching up. The FDA is refining its approach to AI/ML-based Software as Medical Devices. ONC requires algorithm transparency in certified health IT. The EU AI Act classifies healthcare AI as high-risk. CMS is examining AI’s role in coverage determinations. And states are introducing AI-specific healthcare regulations. For organizations building or deploying AI in healthcare, the regulatory landscape in 2026 is a moving target that requires active monitoring and proactive compliance.

Calculate My Project Cost Connect With Experts

Tell Us Your Requirements

Our experts are ready to understand your business goals.

Trusted Partners

Trusted by Industry Leaders Worldwide

Recognition

Awards & Recognitions

FDA Regulation of Healthcare AI

AI/ML-Based SaMD

The FDA regulates AI that meets the definition of Software as a Medical Device — software intended to diagnose, treat, cure, or prevent disease. AI that analyzes medical images to detect pathology, predicts clinical deterioration from vital signs, recommends treatment protocols, or provides diagnostic support falls under FDA jurisdiction.

Current FDA approach: The FDA has cleared/authorized over 950 AI/ML-enabled medical devices (as of 2025), primarily through 510(k) and De Novo pathways. Radiology AI accounts for the largest share, followed by cardiology and pathology.

Predetermined Change Control Plan (PCCP): The FDA allows SaMD developers to describe anticipated algorithm modifications in the original submission. Changes within the PCCP — retraining on new data, updating model weights, refining performance thresholds — can be implemented without a new premarket submission. This is critical for adaptive AI that improves over time.

Total Product Lifecycle (TPLC) approach: The FDA’s TPLC framework for AI/ML envisions continuous monitoring and iterative improvement rather than static, one-time clearance. Developers are expected to monitor real-world performance, identify degradation, and update algorithms — all within a regulatory framework that balances innovation with safety.

Clinical Decision Support Exemptions

Not all healthcare AI requires FDA clearance. CDS software meeting all four criteria of Cures Act Section 3060 — not processing images/signals/patterns, displaying medical information, intended for professionals, enabling independent review — is exempt from device regulation. However, AI that provides autonomous diagnoses or treatment recommendations without professional independent review likely does not meet the exemption.

ONC Algorithm Transparency Requirements

Under ONC’s HTI-1 rule, developers of certified health IT must provide transparency information for clinical decision support interventions — including AI-powered tools. Required disclosures include:

Source attributes: Developer identity, funding sources, and training data characteristics

Intended use: Clinical scenarios the algorithm targets, intended user population, and care settings

Performance information: Accuracy metrics, validation population demographics, and known demographic performance disparities

Limitations: Known failure modes, data quality dependencies, and clinical contexts where the algorithm may underperform

EU AI Act: Healthcare Provisions

The EU AI Act (effective 2024, with phased implementation through 2026) classifies most healthcare AI as high-risk — requiring:

Risk management system: Ongoing identification and mitigation of AI risks throughout the product lifecycle

Data governance: Training and validation data quality requirements, bias assessment, and documentation

Technical documentation: Comprehensive documentation of AI design, development, and validation

Transparency: Users must be informed they’re interacting with AI and understand its capabilities and limitations

Human oversight: Meaningful human oversight of AI decisions, with ability to override or disregard AI outputs

Accuracy and robustness: Documented accuracy levels, robustness testing, and cybersecurity measures

CMS AI Policies

CMS is examining AI’s role in several healthcare contexts:

Coverage determinations. CMS and commercial payers are under scrutiny for using AI algorithms to make coverage and prior authorization decisions. Regulatory and legal actions are pushing toward requirements that AI-driven denials include human review and that algorithms used for coverage decisions be transparent and auditable.

Quality measurement. CMS quality programs are beginning to address how AI-assisted documentation, coding, and clinical decision-making interact with quality measure validity. If AI auto-generates clinical documentation that drives quality scores, the integrity of those scores depends on the accuracy and reliability of the AI.

Risk adjustment. AI tools for ICD-10 HCC coding and risk adjustment are under CMS attention — concerns about AI-driven “upcoding” (identifying diagnoses the clinician didn’t document) could trigger audit and enforcement activity.

Section 05

State-Level AI Healthcare Regulations

Several states have enacted or proposed AI-specific healthcare regulations:

Colorado: Requires disclosure when AI is used in consequential decisions, including healthcare. Developers and deployers must conduct impact assessments for high-risk AI systems.

California: Proposed legislation (SB 1120) requiring transparency for AI used in healthcare delivery and coverage decisions.

New York City: Requires bias auditing for automated decision-making tools (applies to employer health benefit AI tools).

Multiple states: Legislation targeting AI in insurance decisions, prior authorization automation, and clinical documentation.

Compliance Checklist

FDA compliance (for AI SaMD):

SaMD classification completed — AI product assessed against device definition

Regulatory pathway determined (510(k), De Novo, PMA, or exempt)

Predetermined Change Control Plan filed for adaptive AI

Post-market surveillance monitoring operational

Real-world performance monitoring tracking accuracy and bias

How Taction Ensures Compliance

At Taction, our team builds regulatory-compliant healthcare AI systems and helps organizations navigate the evolving AI regulatory landscape.

What we do:

AI regulatory assessment — We evaluate your AI product against FDA SaMD criteria, ONC transparency requirements, EU AI Act provisions, and state regulations — determining your compliance obligations and building a roadmap.

FDA-compliant AI development — We build AI-powered clinical tools with FDA design controls, predetermined change control plans, and post-market monitoring — from concept through clearance.

Algorithm transparency implementation — We build transparency documentation and user-facing disclosure interfaces that satisfy ONC’s HTI-1 requirements for certified health IT.

Bias testing and monitoring — We implement bias testing frameworks that evaluate AI performance across demographic subgroups — detecting disparities before deployment and monitoring for drift in production.

AI governance programs — We help healthcare organizations build AI governance structures — policies, review processes, validation requirements, and monitoring frameworks for responsible AI deployment.